CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

argenx SE

ARGX
$58.82BLarge Cap

Next catalyst

PDUFAJan 3, 2027in 42 days

Efgartigimod

generalized myasthenia gravis

Get an email about ARGX's next catalysts

Track argenx (ARGX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 10 more upcoming events in our data (PDUFA date, Phase 3 readout, Phase 2 readout).See the timeline

Catalyst Timeline

12 upcoming, 2 past

PDUFANext

FDA PDUFA Date efgartigimod alfa-fcab (priority)

Jan 3, 2027Efgartigimod

For generalized myasthenia gravis. BLA filing. Extracted from SEC filing: 6-K

Source
Phase 3
✗Negative

efgartigimod administration Phase 3 Est. Readout

January 2027~efgartigimod administration30

Estimated primary completion for efgartigimod administration trial (NCT06765161) in Myasthaenia Gravis. Topline data typically follows completion by weeks to months.

Phase III Vyvgart Sjögren's study discontinued due to predicted efficacy failure

Source
PDUFA

FDA PDUFA Date VYVGART and VYVGART Hytrulo (efgartigimod alfa) (priority)

February 2027~Efgartigimod

For pediatric generalized myasthenia gravis (gMG). sNDA filing. Extracted from SEC filing: EX-99.1

Source
Phase 3

Efgartigimod IV Phase 3 Est. Readout (ADAPT Jr)

March 2027~Efgartigimod IV15

Estimated primary completion for Efgartigimod IV trial (NCT04833894) in Generalized Myasthenia Gravis. Topline data typically follows completion by weeks to months.

Source
Phase 2

Efgartigimod PH20 SC Phase 2 Est. Readout (ADHERE+)

April 2027~Efgartigimod PH20 SC229

Primary completion for Efgartigimod PH20 SC trial (NCT04280718) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Source
Phase 2

Efgartigimod Alfa Phase 2 Est. Readout (PET-AON)

June 2027~Efgartigimod Alfa20

Estimated primary completion for Efgartigimod Alfa trial (NCT06453694) in Optic Neuritis. Topline data typically follows completion by weeks to months.

Source
Phase 3

Efgartigimod PH20 SC Phase 3 Est. Readout (Unity)

July 2027~Efgartigimod PH20 SC631

Primary completion for Efgartigimod PH20 SC trial (NCT06684847) in Primary Sjogrens Disease

Source
Phase 3

Efgartigimod PH20 SC Phase 3 Est. Readout (ADAPT Jr SC)

September 2027~Efgartigimod PH20 SC12

Estimated primary completion for Efgartigimod PH20 SC trial (NCT06392386) in Generalized Myasthenia Gravis. Topline data typically follows completion by weeks to months.

Source

Upcoming FDA decisions

How ARGX's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸EuropeZWIJNAARDE1.9K employees

Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs.

Website
Drug Pipeline

Frequently asked questions

What is in argenx SE's drug pipeline?→

CatalystAlert tracks 19 drug candidates in argenx SE's (ARGX) pipeline across Phase 3, Phase 2. Its lead program is Efgartigimod (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is argenx SE's next FDA catalyst?→

argenx SE's (ARGX) next tracked catalyst is a PDUFA date expected Jan 3, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track ARGX biotech catalysts?→

Add ARGX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow argenx SE's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply